This suggests that high plasma TGF-β may be a potential biomarker for poor treatment response and outcome to immunotherapy, which may be related to the tumor microenvironment of decreased T-cell infiltration in tumors shaped by TGF-β (61). This evidence concerns the gene TGFB1 and neoplasm.